用于嗜酸性肉芽肿性多血管炎诊断的蛋白质组合物
By screening SERPINA3, FGA, AGP1, ITIH3, and SAA1 proteins as EGPA biomarkers and combining them with multiple detection methods, an EGPA detection kit was constructed, solving the challenges of early diagnosis and activity assessment, and improving diagnostic accuracy and treatment efficacy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHONGSHAN HOSPITAL FUDAN UNIV
- Filing Date
- 2024-01-04
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies make it difficult to diagnose eosinophilic granulomatous polyangiitis (EGPA) early, especially in ANCA-negative patients, and the sensitivity and specificity of traditional biomarkers are limited, leading to treatment difficulties and poor prognosis.
Four proteins, SERPINA3, FGA, AGP1, ITIH3, and SAA1, were screened using proteomics to serve as diagnostic and activity assessment biomarkers for EGPA. An EGPA detection kit was constructed by combining multiple detection methods, such as ELISA and magnetic microparticle chemiluminescence assay, to determine the content or gene expression level of these proteins.
It improves the accuracy of early diagnosis and activity assessment of EGPA, provides higher diagnostic efficacy and predictive potential, reduces the risk of misdiagnosis and missed diagnosis, and supports personalized treatment.
Smart Images
Figure BDA0004649004820000211 
Figure BDA0004649004820000221 
Figure BDA0004649004820000231